The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.

The RSI is a momentum indicator, which compares a stock’s strength on days when prices go up to its strength on days when prices go down. When compared to a stock’s price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered oversold when the RSI is below 30, according to Benzinga Pro.

Here’s the latest list of major oversold players in this sector, having an RSI near or below 30.

Legend Biotech Corp (NASDAQ:LEGN)

  • On July 13, JP Morgan analyst Jessica Fye reinstated Legend Biotech with a Neutral and announced a $35 price target. The company’s stock fell around 20% over the past month and has a 52-week low of $16.25.
  • RSI Value: 28.4
  • LEGN Price Action: Shares of Legend Biotech fell 2% to close at $22.26 on Friday.
  • Edge Stock Ratings: 13.67 Momentum score.

Opus Genetics Inc (NASDAQ:IRD)         

  • On July 6, Opus Genetics announced FDA alignment on Phase 3 registrational trial design for OPGx-LCA5 in LCA5-associated inherited retinal disease. The company’s stock fell around 20% over the past month and has a 52-week low of $1.04.
  • RSI Value: 27.7   
  • IRD Price Action: Shares of Opus Genetics fell 0.3% to close at $3.27 on Friday.
  • Benzinga Pro’s charting tool helped identify the trend in IRD stock.

Anbio Biotechnology (NASDAQ:NNNN)

  • Anbio Biotechnology, during April, reported full-year 2025 results, with sales rising to $8.65 million from $8.19 million in 2024. The company’s stock fell around 43% over the past month and has a 52-week low of $8.30.
  • RSI Value: 26.6
  • NNNN Price Action: Shares of Anbio Biotechnology fell 1.2% to close at $9.49 on Friday.
  • Benzinga Pro’s signals feature notified of a potential breakout in NNNN shares.

BZ Edge Rankings: Find out where other stocks stand—explore the full comparison now.

Photo via Shutterstock